Analyst Price Targets — VRCA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 18, 2025 8:41 am | Kemp Dolliver | Loop Capital Markets | $17.00 | $8.05 | StreetInsider | Brookline Capital Markets Upgrades Verrica Pharmaceuticals (VRCA) to Buy |
| May 14, 2024 9:35 am | Glen Santangelo | Jefferies | $12.00 | $11.28 | StreetInsider | Verrica Pharmaceuticals (VRCA) PT Raised to $12 at Jefferies |
| May 14, 2024 6:51 am | Oren Livnat | H.C. Wainwright | $14.00 | $9.56 | StreetInsider | Verrica Pharmaceuticals (VRCA) PT Raised to $14 at H.C. Wainwright |
| July 25, 2023 1:03 pm | Serge Belanger | Needham | $10.00 | $5.32 | Benzinga | Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval |
Latest News for VRCA
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m.
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, two have assigned a buy recommendation and one has assigned
WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston.
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer.
WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VRCA.
U.S. House Trading
No House trades found for VRCA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.